A recent study shows that Bristol Myers Squibb’s oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was associated with noticeable improvements in signs and symptoms of psoriatic arthritis compared with placebo.

Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.

Almost no health topic was off limits at Chronicon, a first-of-its kind day-long event that brought together today’s most impactful health influencers specializing in chronic health conditions for an open forum to address the needs of those living with chronic conditions and their support communities.

Novartis released positive data from the company’s FUTURE 5 clinical trial of Cosentyx (secukinumab) in psoriatic arthritis.